- Home
- ASC vs ERAS Comparison
ASC vs ERAS Comparison
Compare ASC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASC | ERAS |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.7M | 927.7M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASC | ERAS |
|---|---|---|
| Price | $11.20 | $3.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $13.67 | $3.71 |
| AVG Volume (30 Days) | 592.0K | ★ 2.0M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 8.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $309,326,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.32 | $1.01 |
| 52 Week High | $13.85 | $3.62 |
Technical Indicators
Market Signals| Indicator | ASC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 33.24 | 67.68 |
| Support Level | $11.07 | $3.15 |
| Resistance Level | $11.34 | $3.80 |
| Average True Range (ATR) | 0.29 | 0.25 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 7.29 | 79.29 |
Price Performance
Historical ComparisonAbout ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.